IDOV-Safe™, the core product of Longyao Biotechnology, is currently undergoing clinical trials at three out of the top four oncology centers in China. It has achieved a historic breakthrough in the treatment of microsatellite-stable (MSS) colorectal cancer and demonstrated significant therapeutic potential in the treatment of refractory malignancies including triple-negative breast cancer, non-small cell lung cancer, and cardiac orifice cancer. IDOV-Immune™, the company’s upgraded strategic product, has had its Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA), and dosing has commenced in Phase I clinical trials in Australia. With its proprietary mechanism design and preclinical data across multiple cancer types that are markedly superior to those of its predecessor, this product stands a greater chance of achieving successive revolutionary breakthroughs in the treatment of a broader range of refractory advanced metastatic solid tumors.